2013 Molecular Pharmacology Gordon Research Conference and Gordon Research Semina

描述（由申请人提供）：分子药理学戈登研究会议（GRC）是一个重要的论坛，聚集了来自G蛋白偶联受体（GPCR）研究的基础，应用和临床科学的科学家。在此，我们请求对2013年第24届GRC会议的部分支持，该会议将包括GRC会议和最近举行的戈登会议研究研讨会（GRS）。GRC/GRS 2013的具体目标是吸引来自学术界和工业界的最优秀的科学家讨论该领域的重大发展，鼓励对该领域最新和有争议的想法进行公开讨论，促进在转化机会领域的合作工作，并为博士生，博士后和初级科学家提供一个高效的论坛，分享他们的成果并与更资深的同事互动。分子药理学GRC传统上在美国和欧洲轮流举行，GRC/GRS 2013将在托斯卡纳（意大利的Il Ciocco）举行。会议将强调该领域的新兴和快速发展的领域。2013年计划的创新包括强调与生理学相关的机制，对不寻常的gpcr或模型系统的讨论，以及解决单分子动物生物学和人类疾病的前沿方法的介绍。具体来说，该计划将涵盖四个主要领域：i)受体和受体复合物的结构动力学，包括单分子水平的研究，ii)细胞和体内配体偏态信号，以及新的方法

DESCRIPTION (provided by applicant): The Molecular Pharmacology Gordon Research Conference (GRC) is a key forum gathering scientists from basic, applied and clinical science in G protein coupled receptor (GPCR) research. Here we request partial support for the 2013 conference, 24th GRC edition, which will include both the GRC and the recently adjoined Gordon Conference Research Seminar (GRS). Specific aims of GRC/GRS 2013 seek to attract the very best scientists from academic and industrial worlds to discuss major developments in the field, encourage open discussions on latest and also controversial ideas in the field, facilitae collaborative work in areas of translational opportunities, and serve as a highly effective forum for doctoral students, post-docs and junior scientists to share their results and interact with mor senior colleagues. The Molecular Pharmacology GRC traditionally alternates between US and Europe, and the GRC/GRS 2013 will be held in Tuscany (Il Ciocco, Italy). The conference will emphasize both emerging and rapidly growing areas in the field. Innovation in the 2013 program includes a strong emphasis on mechanisms relevant to physiology, discussion on unusual GPCRs or model systems, and the presentation of cutting-edge methodologies addressing single molecules to animal biology and human diseases. Specifically the program will cover four main areas: i) structural dynamics of receptors and receptor complexes including studies at the single molecule level, ii) ligand-biased signaling in cellular and in vivo, and novel approaches to physiology with an emphasis on animal models, (iii) novel opportunities for drug development and therapeutics, including the identification of GPCRs linked to human diseases and (iv) orphan and atypical GPCRs, revealing new mode of action of these important signaling proteins. Methodological aspects will include novel physical and computing approaches, the development of innovative biosensors and light-controlled processes, and novel therapeutic strategies. The conference will gather about 150 speakers and attendees and the anticipated outcome is cross-fertilization of ideas and techniques, towards enhanced understanding of GPCR biology and associated diseases.